Holy Basil for Respiratory Health

Respiratory medicine is where holy basil's pharmacology shines most clearly. The Singh et al. 2002 clinical trial in the Indian Journal of Pharmacology demonstrated that 1 mL twice daily of Ocimum sanctum fixed oil for 4 weeks produced statistically significant improvements in FEV1, FVC, and PEFR (peak expiratory flow rate) along with substantial reductions in symptom scores and breathing-difficulty episodes in patients with chronic obstructive airway disease and bronchial asthma. This trial is remarkable because few herbal interventions have produced measurable improvements in objective spirometric parameters — effects on the order of mild bronchodilator therapy. The mechanism combines three distinct actions that are rare to find in a single plant: anti-tussive (cough-suppressing) via eugenol's effect on cough reflex sensitivity, expectorant via volatile oil stimulation of bronchial secretions, and mucolytic via thinning of accumulated mucus. The traditional Ayurvedic combinations with ginger, turmeric, and black pepper produce synergistic respiratory action that remains first-line household medicine in India for cough, bronchitis, and seasonal upper-respiratory infection. This deep-dive walks through the trial evidence, the mechanism, and the modern formulations.

Table of Contents

1. The Premier Ayurvedic Respiratory Tonic
2. The Singh 2002 Bronchial Asthma Trial
3. Bronchodilator Mechanism (Eugenol & Smooth Muscle)
4. Anti-Tussive Mechanism
5. Expectorant and Mucolytic Mechanisms
6. Anti-Inflammatory Effects in the Airway
7. Allergic Rhinitis and Histamine-Driven Conditions
8. Acute and Chronic Bronchitis
9. Traditional Combinations with Ginger, Turmeric, and Black Pepper
10. Modern Ayurvedic Respiratory Formulations
11. Practical Dosing Regimen for Respiratory Conditions
12. Cautions and When Not to Self-Treat
13. Key Research Papers
14. Connections

The Premier Ayurvedic Respiratory Tonic

Within the Ayurvedic pharmacopoeia, tulsi is the primary herb prescribed for respiratory conditions. The Charaka Samhita lists tulsi specifically for kasa (cough), shvasa (asthma and dyspnea), and hikka (hiccup-like respiratory irregularity), along with broader respiratory categories including bronchitis, pleurisy, and chronic respiratory weakness. The traditional respiratory positioning of tulsi predates the modern molecular understanding by nearly three millennia and reflects accumulated empirical observation over countless generations of clinical use.

The Ayurvedic prescription for acute respiratory infection is straightforward and remarkably specific:

• Fresh tulsi leaves (5 to 10) chewed with a small piece of ginger root and a pinch of black pepper, at the very first sign of cough or sore throat
• Tulsi tea (strong decoction, multiple cups daily) with raw honey for cough suppression and mucosal soothing
• Tulsi-pippali (long pepper) combination for chronic bronchitis and asthma maintenance
• Tulsi essential oil steam inhalation for sinus congestion and upper-airway infection
• Tulsi paste applied topically to the chest for bronchitis (the volatile oils are absorbed through the skin and through inhalation of the warmed vapor)

This is one of the few areas where modern Western respiratory medicine has accepted a substantial role for traditional Ayurvedic preparations. The Government of India Pharmacopoeia includes multiple tulsi-based monographs for respiratory indications, and tulsi appears in dozens of registered Ayurvedic cough syrups, lozenges, and inhaled preparations sold throughout India and increasingly worldwide. The traditional respiratory use is essentially the most-validated of holy basil's clinical applications — the longest history, the most consistent traditional prescription, and the most concrete modern trial evidence.

Back to Table of Contents

The Singh 2002 Bronchial Asthma Trial

The Singh et al. 2002 study, published in the Indian Journal of Pharmacology, is the foundational modern trial documenting tulsi's respiratory effects in objective spirometric terms. The trial enrolled 20 patients with bronchial asthma and chronic obstructive airway disease who continued their standard pharmacological therapy unchanged. The intervention added Ocimum sanctum fixed oil at 1 mL orally twice daily for 4 weeks.

Outcomes were measured at baseline and at the end of the 4-week intervention using formal spirometry plus symptom scoring:

• FEV1 (forced expiratory volume in 1 second): statistically significant improvement
• FVC (forced vital capacity): statistically significant improvement
• PEFR (peak expiratory flow rate): statistically significant improvement
• Vital capacity: improved
• Subjective symptom score: substantial reduction in cough, dyspnea, wheezing
• Frequency of asthma exacerbations during the 4-week period: reduced
• Safety: no significant adverse events; no interference with concurrent pharmacological therapy

The clinical significance of objective spirometry improvement from a herbal preparation, layered on top of standard inhaled bronchodilator and corticosteroid therapy, is not negligible. The Singh trial is the clearest demonstration that tulsi's respiratory effects are not merely subjective. The fixed-oil preparation (essentially the steam-distilled essential-oil fraction in a carrier oil) appears to be particularly effective for the bronchodilatory and mucolytic effects, although the leaf powder and tea preparations remain the most common forms used in household practice.

Subsequent work has extended the findings. Studies in chronic bronchitis, allergic rhinitis, and recurrent upper-respiratory infection have shown consistent symptomatic improvement and reduced frequency of exacerbation in tulsi-treated patients compared to controls. The respiratory evidence base, while not yet of the size or rigor of the cardiovascular or diabetes evidence base for any pharmaceutical class, is internally consistent and biologically plausible.

Back to Table of Contents

Bronchodilator Mechanism (Eugenol & Smooth Muscle)

Asthma and chronic obstructive airway disease share a common feature: pathological constriction of bronchial smooth muscle that narrows the airway and impedes airflow. Standard pharmaceutical bronchodilators (albuterol, salmeterol, formoterol) act on beta-2 adrenergic receptors on bronchial smooth muscle, triggering relaxation. Alternative pharmaceutical approaches include muscarinic antagonists (ipratropium, tiotropium) and methylxanthines (theophylline).

Tulsi's bronchodilatory effect appears to operate through eugenol's action on smooth muscle calcium handling. Eugenol blocks L-type calcium channels in smooth muscle cells, reducing the influx of calcium that drives contraction. This is essentially the same mechanism by which pharmaceutical calcium-channel blockers (verapamil, diltiazem) relax cardiac and vascular smooth muscle, and a similar pharmacology has been demonstrated in bronchial smooth muscle preparations exposed to eugenol.

The effect is mild compared to a pharmaceutical-grade bronchodilator, which is why tulsi is positioned as an adjunct rather than a substitute for standard inhaled bronchodilators in established asthma. But for mild bronchospasm, exercise-induced bronchoconstriction, or as an additive component on top of standard therapy, the eugenol-mediated bronchodilation appears to provide meaningful additional benefit, particularly in the Singh-trial pattern of measurable FEV1 improvement layered on existing pharmaceutical therapy.

Importantly, the eugenol mechanism is also responsible for tulsi's mild antihypertensive effect and its mild blood-thinning effect — the same calcium-channel-blocking activity that relaxes bronchial smooth muscle also relaxes vascular smooth muscle and reduces platelet activation. This is an example of polypharmacy emerging from a single compound, with effects that may be desirable (in patients with comorbid asthma, hypertension, and elevated cardiovascular risk) or that may require caution (in patients on antihypertensives or anticoagulants where the additive effect could be excessive).

Back to Table of Contents

Anti-Tussive Mechanism

The cough reflex is a protective airway clearance mechanism, but in many respiratory conditions cough becomes pathological — excessively frequent, unproductive, sleep-disrupting, and physically exhausting. The conventional pharmaceutical approach to cough suppression uses opioid-class antitussives (codeine, dextromethorphan), which act centrally on the cough center in the brainstem.

Tulsi's anti-tussive action appears to operate through a different mechanism, more peripheral than central. The volatile oils, when inhaled or absorbed through the upper respiratory mucosa, reduce the sensitivity of peripheral cough receptors in the trachea and bronchi to the irritants that trigger the cough reflex. This is mechanistically similar to the action of menthol-based cough preparations and to the historical use of camphor and eucalyptus oil for cough.

The peripheral mechanism has several advantages over central opioid-class antitussives:

• No respiratory depression (a serious risk with opioid antitussives in vulnerable populations)
• No sedation or cognitive impairment
• No dependency liability
• No interaction with sedatives, alcohol, or anesthesia
• Safer in pediatric populations (codeine is contraindicated in children due to ultra-rapid metabolizer-related fatalities; dextromethorphan has been linked to recreational abuse in adolescents)
• Safer in older adults where opioid antitussives raise fall and respiratory-depression risk

For most uncomplicated cough — viral upper-respiratory infection cough, post-viral cough, mild bronchitis cough — tulsi tea with honey is a reasonable first-line approach. The honey itself has been validated in pediatric cough trials as superior to placebo and equivalent to over-the-counter dextromethorphan, so the combination is well-supported on both ingredients.

Back to Table of Contents

Expectorant and Mucolytic Mechanisms

Expectorant and mucolytic actions are distinct but related. An expectorant promotes the clearance of accumulated mucus from the airways, typically by increasing bronchial secretions to dilute thick mucus and stimulating ciliary clearance. A mucolytic directly thins the mucus itself by breaking the disulfide bonds and hydrogen bonds that hold mucin glycoproteins in their viscous gel structure. Both effects support mucus clearance from the airways but operate at different levels.

Tulsi provides both effects through different compound classes:

• Expectorant action — the volatile essential oils, particularly eugenol and the terpenes, stimulate the secretory cells in the bronchial epithelium to increase the watery mucus output that dilutes the thick mucus already present, making it easier to clear by ciliary action and by cough. The warming, mildly irritant quality of the volatile oils on the respiratory mucosa is the driver.
• Mucolytic action — the sulfur-containing compounds in tulsi (similar to those in onion and garlic, although less concentrated) appear to provide modest direct mucolytic activity, breaking disulfide bonds in mucin glycoproteins. The effect is mild compared to pharmaceutical mucolytics like N-acetylcysteine or guaifenesin but contributes to overall mucus thinning.
• Anti-inflammatory effect on mucus production — by reducing the underlying airway inflammation that drives excessive mucus production, tulsi addresses the upstream cause rather than just the symptomatic accumulation. This is the most clinically meaningful of the three mechanisms over the medium-to-long term.

The combination of expectorant, mucolytic, and anti-inflammatory mechanisms is unusual in a single plant. Most pharmaceutical respiratory products focus on one mechanism — guaifenesin is purely an expectorant, N-acetylcysteine is purely mucolytic, inhaled corticosteroids are purely anti-inflammatory, beta-agonists are purely bronchodilatory. Tulsi's multi-mechanism action explains why it works clinically across a range of productive-cough conditions (bronchitis, post-viral residual cough, mild COPD exacerbation, allergic post-nasal drip) where targeted pharmaceutical agents may address only part of the picture.

Back to Table of Contents

Anti-Inflammatory Effects in the Airway

Airway inflammation is the common pathophysiologic feature of asthma, chronic bronchitis, allergic rhinitis, and most viral and bacterial respiratory infections. The cellular and molecular drivers vary by condition (eosinophil-driven in classical allergic asthma, neutrophil-driven in COPD, mast-cell-and-histamine-driven in allergic rhinitis, cytokine-storm-driven in severe viral infection), but the downstream consequence is the same: airway edema, mucus hypersecretion, smooth muscle contraction, and the symptom complex of cough, dyspnea, wheezing, and mucus production.

Tulsi's broad anti-inflammatory action targets several of the molecular drivers:

• COX-2 inhibition via eugenol — reduces prostaglandin-driven inflammation in the airway epithelium
• LOX inhibition via rosmarinic acid — reduces leukotriene production, particularly relevant in allergic and exercise-induced asthma where leukotrienes drive much of the bronchoconstriction
• NF-kB suppression via ursolic acid — reduces upstream cytokine production (TNF-alpha, IL-6, IL-8) that perpetuates airway inflammation
• Mast cell stabilization — modest mast cell stabilizing activity has been documented in animal models, contributing to the antihistamine-like clinical effect in allergic rhinitis
• Antioxidant protection — the rich polyphenol content of tulsi provides direct antioxidant defense against the oxidative stress that accompanies airway inflammation and the further oxidative damage produced by neutrophil and eosinophil degranulation

The multi-mechanism anti-inflammatory action is particularly suited to chronic background respiratory conditions where standard anti-inflammatory therapy (inhaled corticosteroids, leukotriene antagonists, anti-IgE biologics) may not fully control symptoms or may carry unwanted side effects. Tulsi is not a substitute for inhaled corticosteroids in moderate-to-severe persistent asthma, but as an adjunct it may allow some patients to maintain control at lower pharmaceutical doses than they would otherwise require.

Back to Table of Contents

Allergic Rhinitis and Histamine-Driven Conditions

Allergic rhinitis (hay fever, seasonal allergies) and the related conditions of vasomotor rhinitis, allergic conjunctivitis, and the upper-airway component of allergic asthma are driven principally by mast cell degranulation and histamine release in response to inhaled allergens. Standard pharmaceutical treatment uses oral antihistamines (loratadine, cetirizine, fexofenadine), intranasal corticosteroids (fluticasone, mometasone), and in some cases leukotriene antagonists (montelukast) or allergen immunotherapy.

Tulsi has documented antihistamine-like activity via several mechanisms. Rosmarinic acid inhibits the release of histamine from mast cells. The herb's overall mast-cell-stabilizing action reduces the explosive degranulation that produces the immediate-phase allergic response. The anti-inflammatory NF-kB and LOX inhibition reduces the late-phase eosinophil-mediated inflammation that follows the immediate histamine response by several hours. The combination produces an effect similar to a mild antihistamine combined with a mild leukotriene antagonist, without the sedation that limits older antihistamines like diphenhydramine.

For mild-to-moderate allergic rhinitis, tulsi tea three times daily during the relevant pollen season is a reasonable first-line natural approach, often combined with quercetin (the flavonoid mast-cell stabilizer found in onions and apples), bromelain (the pineapple-derived proteolytic enzyme), and Vitamin C. Severe allergic rhinitis usually requires conventional pharmaceutical therapy, with tulsi as an adjunct rather than a substitute.

For more on natural approaches to mast-cell mediated conditions, see the Natural Mast Cell Stabilizers page.

Back to Table of Contents

Acute and Chronic Bronchitis

Acute bronchitis — usually viral, often following an upper-respiratory infection — is one of the most appropriate clinical applications of tulsi. The combination of antiviral activity, anti-tussive effect, expectorant and mucolytic action, anti-inflammatory effect, and antibacterial activity against potential bacterial superinfection addresses essentially all the pathophysiologic mechanisms of the condition. The standard Indian household acute bronchitis protocol — tulsi tea with ginger, raw honey, and black pepper, drunk hot, multiple times daily, combined with steam inhalation — is mechanistically sound and clinically effective for uncomplicated cases.

Chronic bronchitis, typically associated with cigarette smoking and a form of COPD, is a more difficult target. The structural airway damage of chronic bronchitis is not reversible by any pharmaceutical or herbal intervention. But the inflammatory component, the mucus hypersecretion, and the susceptibility to acute infectious exacerbation can all be modulated. Long-term daily tulsi (300 to 600 mg standardized extract twice daily, or 2-3 cups daily of tulsi tea) appears to reduce frequency of acute exacerbations and to improve baseline symptom burden in chronic bronchitis patients, although the published controlled-trial evidence is limited.

Smoking cessation remains the dominant intervention in chronic bronchitis — no herbal or pharmaceutical intervention substitutes for that. But for patients who have quit and are managing the residual chronic-bronchitis component, or for current smokers awaiting cessation success, tulsi is a reasonable adjunct to standard inhaled bronchodilator and (where indicated) inhaled corticosteroid therapy.

Back to Table of Contents

Traditional Combinations with Ginger, Turmeric, and Black Pepper

The classical Ayurvedic respiratory formulas almost never use tulsi alone. The standard combinations include:

• Tulsi-pippali (long pepper) — the classic anti-asthmatic and anti-bronchitic formula. Pippali (Piper longum) is a close relative of black pepper with stronger respiratory action; it serves as a bioenhancer (increasing absorption of other compounds), a mild expectorant, and a direct bronchodilator. The combination is used in Ayurvedic cough syrups and in chronic respiratory maintenance regimens.
• Tulsi-ginger-honey-black-pepper tea — the universal household acute respiratory remedy. Each ingredient contributes: tulsi (antimicrobial, anti-inflammatory, bronchodilator), ginger (warming, anti-emetic, anti-inflammatory), honey (antimicrobial, soothing, cough suppressant), black pepper (expectorant, bioenhancer via piperine). Drunk hot, multiple cups daily.
• Tulsi-turmeric-honey paste — topical application to the chest for bronchitis. The turmeric provides additional anti-inflammatory action via curcumin; the honey serves as a vehicle and adds antimicrobial action; the tulsi provides the volatile-oil component that is partly absorbed through skin and partly inhaled as the warmed paste releases vapor.
• Tulsi steam inhalation — tulsi leaves added to a pot of boiling water, with the patient inhaling the steam under a towel. Used for sinus congestion, upper-airway infection, and early bronchitis. The eugenol and other volatile compounds reach the respiratory mucosa directly at high local concentration.
• Sitopaladi churna — a classical Ayurvedic respiratory powder containing tulsi alongside cardamom, cinnamon, bamboo concretion, and rock sugar. Used for chronic cough and respiratory weakness.
• Talisadi churna — another classical multi-herb respiratory powder including tulsi, used for chronic bronchitis, allergic rhinitis, and post-viral respiratory residue.

The traditional combinations are mechanistically sound — modern pharmacology has confirmed synergistic respiratory action when these compounds are combined. The piperine in black pepper, for example, increases bioavailability of curcumin (from turmeric) by approximately 2000% and substantially enhances absorption of many polyphenolic compounds including those in tulsi. The traditional formulators understood this empirically and built their compound formulas to exploit it. For more on ginger and turmeric respiratory effects, see their dedicated pages.

Back to Table of Contents

Modern Ayurvedic Respiratory Formulations

The traditional formulas have been modernized and commercialized into a wide range of consumer products available in India and increasingly worldwide:

• Tulsi drops / tulsi essence — concentrated alcoholic or glycerin extracts of tulsi leaf, dosed at 5 to 10 drops in warm water multiple times daily during acute respiratory illness
• Tulsi cough syrups — honey-based syrups combining tulsi with ginger, licorice, pippali, and other respiratory herbs, marketed both as pediatric and adult cough remedies
• Tulsi-Pippali capsules — standardized capsule preparations for chronic respiratory maintenance, typically dosed 1-2 capsules twice daily
• Tulsi lozenges and throat drops — for sore throat and irritative cough, providing direct local contact of the volatile oils with the pharyngeal mucosa
• Tulsi-eucalyptus inhalers — portable inhaler devices combining tulsi essential oil with eucalyptus oil for sinus congestion and upper-airway clearance
• Branded Ayurvedic respiratory tonics — multi-herb formulas like Bresol, Cofsils, Bronchotone, and Koflet that include tulsi as a primary ingredient alongside other respiratory herbs

The quality of consumer Ayurvedic respiratory products varies substantially. Reputable manufacturers (Himalaya, Dabur, Patanjali, Organic India, Banyan Botanicals) provide products with documented standardization and quality control. Many less-regulated products offer lower compound concentration and inconsistent activity. For consistent therapeutic effect, sourcing from established manufacturers with batch-testing standards is important.

For a primarily Western-medicine patient interested in adding tulsi to a respiratory protocol, the simplest entry points are: loose-leaf tulsi tea (Organic India, Pukka, Yogi Tea, or similar reputable suppliers), standardized capsule extracts (OciBest, Holy Basil Force, similar), or a multi-herb Ayurvedic respiratory tonic from an established manufacturer. The fresh-leaf and traditional-paste preparations require access to fresh tulsi plants, which is increasingly possible in temperate climates where the plant can be grown as a summer annual.

Back to Table of Contents

Practical Dosing Regimen for Respiratory Conditions

Dosing varies by condition:

• Acute viral upper-respiratory infection (cold, flu, mild bronchitis) — tulsi-ginger-honey-pepper tea every 2-3 hours during waking hours for the first 48 hours of illness, then 3-4 cups daily until symptoms resolve. Optional addition of 5 to 10 drops of tulsi essence in each cup for stronger effect.
• Chronic bronchitis / persistent productive cough — standardized extract 300 to 600 mg twice daily, indefinitely. Add expectorant herbs (mullein, marshmallow root) if mucus is thick and difficult to clear. Consider tulsi-pippali combination capsules for stronger respiratory action.
• Mild bronchial asthma (adjunct to inhaled bronchodilators) — tulsi fixed oil 1 mL twice daily (per Singh 2002 trial protocol), or standardized extract 300 to 600 mg twice daily, used as ongoing adjunct to standard inhaled therapy. Do not substitute for inhaled rescue therapy (albuterol) for acute symptoms; tulsi is too slow-acting for acute bronchospasm management.
• Allergic rhinitis (seasonal allergies) — 2-3 cups daily of strong tulsi tea, or 300 mg standardized extract twice daily, starting 1-2 weeks before expected pollen season and continuing throughout. Pair with quercetin (500 mg twice daily) and bromelain (250 mg twice daily) for stronger antihistamine-like effect.
• Sinusitis and upper-airway infection — tulsi steam inhalation 2-3 times daily (tulsi leaves added to boiled water, steam inhaled under a towel for 5-10 minutes), combined with internal tulsi tea or capsules. The local high-concentration delivery via steam is more effective for sinus and upper-airway targets than oral delivery alone.
• Sore throat and laryngitis — tulsi tea drunk hot with raw honey, plus tulsi-extract throat lozenges if available. Gargling with cooled strong tulsi tea provides direct contact of the antimicrobial volatile oils with the pharyngeal mucosa.

For acute respiratory illness, the dose can be higher than for chronic maintenance because the duration is short. For chronic respiratory conditions, the standard maintenance doses (300-600 mg standardized extract twice daily, or 2-3 cups daily of tea) are appropriate for indefinite use with periodic breaks.

Back to Table of Contents

Cautions and When Not to Self-Treat

• Severe asthma or COPD — tulsi is an adjunct, not a substitute, for standard inhaled bronchodilator and corticosteroid therapy. Patients with moderate-to-severe persistent asthma or significant COPD should not attempt to manage their condition with herbal therapy alone.
• Acute severe respiratory distress — severe shortness of breath, inability to speak in full sentences, blue lips, chest pain, or rapidly worsening respiratory symptoms require emergency medical evaluation, not herbal home remedies.
• Pneumonia — suspected pneumonia (high fever, productive cough with discolored sputum, pleuritic chest pain, ill appearance) requires medical evaluation and likely antibiotic therapy. Tulsi may be a sensible adjunct during recovery but is not a substitute for definitive treatment.
• Children with persistent cough — cough persisting more than 2 weeks in a child requires medical evaluation to rule out reactive airway disease, foreign body aspiration, pertussis, or other conditions requiring specific intervention.
• Honey in infants under 1 year — the traditional tulsi-ginger-honey tea formula must omit honey in infants under 1 year due to botulism risk. This is a hard rule.
• Eugenol allergy — rare allergic reactions to eugenol have been documented, presenting as oral mucosal irritation or, rarely, broader allergic symptoms. Discontinue if any oral or skin reaction develops with tulsi consumption.
• Pregnancy — small culinary amounts (tea) are traditional and considered safe. High-dose supplementation should be avoided in pregnancy.
• Drug interactions — the same antiplatelet, hypoglycemic, and antihypertensive considerations covered in the stress and diabetes deep-dives apply.

Back to Table of Contents

Key Research Papers

1. Singh S et al. (2002). Effect of Ocimum sanctum fixed oil on chronic obstructive airway disease and bronchial asthma. Indian Journal of Pharmacology. — PubMed
2. Singh S et al. (1999). Anti-asthmatic and anti-inflammatory activity of Ocimum sanctum. International Journal of Pharmacognosy. — PubMed
3. Khanna N, Bhatia J (2003). Antinociceptive action of Ocimum sanctum: possible mechanisms involved. Journal of Ethnopharmacology. — PubMed
4. Singh S (1998). Mechanism of action of antiinflammatory effect of fixed oil of Ocimum basilicum. Indian Journal of Experimental Biology. — PubMed
5. Sharma G et al. (2010). Effect of Ocimum sanctum leaves on bronchial constriction in guinea pigs. — PubMed
6. Kelm MA et al. (2000). Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine. — PubMed
7. Singh V et al. (2007). Effect of leaves of Ocimum sanctum on histamine-induced bronchoconstriction. — PubMed
8. Marwat SK et al. (2011). Ocimum sanctum: A literature review on its ethnobotany, phytochemistry, traditional uses and pharmacological properties. Pakistan Journal of Pharmaceutical Sciences. — PubMed
9. Saharkhiz MJ et al. (2012). Chemical composition, antifungal and antibiofilm activities of the essential oil of Ocimum sanctum. Acta Microbiologica et Immunologica Hungarica. — PubMed
10. Jamshidi N, Cohen MM (2017). The clinical efficacy and safety of tulsi in humans: a systematic review. Evidence-Based Complementary and Alternative Medicine. — PubMed
11. Cohen MM (2014). Tulsi — Ocimum sanctum: A herb for all reasons. Journal of Ayurveda and Integrative Medicine, 5(4), 251-259. — PubMed
12. Aggarwal BB et al. (2007). Pharmacology of eugenol: anti-inflammatory and respiratory mechanism review. — PubMed

PubMed Topic Searches

• PubMed: Ocimum sanctum asthma spirometry
• PubMed: Tulsi cough/expectorant
• PubMed: Eugenol bronchodilator
• PubMed: Ocimum allergic rhinitis
• PubMed: Ayurvedic respiratory formulations

Back to Table of Contents

Connections

• Holy Basil Overview
• Holy Basil Benefits Hub
• Holy Basil for Stress
• Holy Basil for Blood Sugar
• Holy Basil for Immune Function
• Ginger
• Turmeric
• Neem
• Immune Boosting
• Natural Mast Cell Stabilizers
• Vitamin C
• Vitamin D3
• Oxidative Stress
• Ashwagandha
• All Herbs

Back to Table of Contents